This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Email: (change)

Frequency:

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2022 Jun;20(6):735-736.

doi: 10.6004/jnccn.2022.7031.

Frailty and Diffuse Large B-Cell Lymphoma: Where Do We Go From Here?

P Connor Johnson

PMID: 35714672
DOI: 10.6004/jnccn.2022.7031

Comment

Frailty and Diffuse Large B-Cell Lymphoma: Where Do We Go From Here?

P Connor Johnson. J Natl Compr Canc Netw. 2022 Jun.

. 2022 Jun;20(6):735-736.

doi: 10.6004/jnccn.2022.7031.

Author

P Connor Johnson

PMID: 35714672
DOI: 10.6004/jnccn.2022.7031

No abstract available

PubMed Disclaimer

Comment on

Frailty in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Receiving Curative-Intent Therapy: A Population-Based Study.
Vijenthira A, Mozessohn L, Nagamuthu C, Liu N, Blunt D, Alibhai S, Prica A, Cheung MC. Vijenthira A, et al. J Natl Compr Canc Netw. 2022 Jun;20(6):635-642.e9. doi: 10.6004/jnccn.2022.7014. J Natl Compr Canc Netw. 2022. PMID: 35714676

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Sheridan PubFactory

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Frailty and Diffuse Large B-Cell Lymphoma: Where Do We Go From Here?

Frailty and Diffuse Large B-Cell Lymphoma: Where Do We Go From Here?

Author

Comment on

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources